Gene expression study of Aurora-A reveals implication during bladder carcinogenesis and increasing values in invasive urothelial cancer.

OBJECTIVES Urothelial carcinoma is a frequent and aggressive cancer. We wanted to gain better insight into the early molecular mechanisms of bladder carcinogenesis by evaluating Aurora-A gene expression, which is implicated in genomic stability and essential for mitosis. MATERIALS This study, using real-time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), analyzed the expression levels of three selected genes in dissected tissues from normal bladder, noninvasive cancers, and muscle-invasive bladder carcinomas (n = 49). We compared gene expression levels of three genes (Aurora-A, and as control uroplakin II (UPII) and TBP, respectively) at different stages of bladder cancer. We used multivariate analysis, receiver operating characteristic curves and the nonparametric Mann-Whitney test. RESULTS The expression of Aurora-A gene studied was significantly deregulated, with an increasing level in cancer versus normal tissue Aurora-A. This development was linear. Aurora-A was already deregulated in early stages of carcinogenesis (pTa/pT1) (P = 0.0004) and displayed even more deregulation in muscle-invasive stages (pT2 to pT4). Immunohistochemistry performed on the same samples using Aurora-A antibody confirmed results of RT-PCR, with statistically significant values when comparing m-RNA expression and immunohistochemical values (P = 0.0001). CONCLUSIONS This study highlights the fact that Aurora-A gene expression is already strongly deregulated in early stages of urothelial carcinoma with abnormal expression, and might be considered a biomarker of tumor aggression. The increase in Aurora-A expression might provide further information regarding the behavior of bladder cancer in daily practice.

[1]  Chi-Ying F. Huang,et al.  Aurora-A overexpression associates with Ha-ras codon-12 mutation and blackfoot disease endemic area in bladder cancer. , 2006, Cancer letters.

[2]  Ekaterini Blaveri,et al.  Bladder cancer outcome and subtype classification by gene expression. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  Chiao-Ying Lin,et al.  Overexpression and Amplification of Aurora-A in Hepatocellular Carcinoma , 2004, Clinical Cancer Research.

[4]  A. Böhle,et al.  Bladder cancer. II. Molecular aspects and diagnosis. , 2001, European urology.

[5]  Hideyasu Matsuyama,et al.  Biological Characteristics in Bladder Cancer Depend on the Type of Genetic Instability , 2006, Clinical Cancer Research.

[6]  D. Chopin,et al.  [Natural history of superficial bladder tumors]. , 2001, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[7]  T. Nojima,et al.  Centrosome hyperamplification and chromosomal instability in bladder cancer. , 2003, European urology.

[8]  J. Cheville,et al.  Evidence for oligoclonality and tumor spread by intraluminal seeding in multifocal urothelial carcinomas of the upper and lower urinary tract , 2001, Oncogene.

[9]  K. Williamson,et al.  Oligoclonality in bladder cancer: the implication for molecular therapies. , 2004, The Journal of urology.

[10]  C. Busch,et al.  Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. , 2001, The Journal of urology.

[11]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[12]  Hideyasu Matsuyama,et al.  Centrosome Hyperamplification Predicts Progression and Tumor Recurrence in Bladder Cancer , 2004, Clinical Cancer Research.

[13]  Daniel C. Ducat,et al.  Aurora kinases in spindle assembly and chromosome segregation. , 2004, Experimental cell research.

[14]  V. Bécette,et al.  Prognostic Value of MIB–1 Antibody Labeling Index to Predict Response to Bacillus Calmette–Guérin Therapy in a High–Risk Selected Population of Patients with Stage T1 Grade G3 Bladder Cancer , 2000, European Urology.

[15]  I. Sesterhenn,et al.  World health organization classifications of tumours. pathology and genetics of tumours of the urinary system and male genital organs , 2005 .

[16]  R. Cheney,et al.  Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[17]  Feng Jiang,et al.  Amplification/overexpression of a mitotic kinase gene in human bladder cancer. , 2002, Journal of the National Cancer Institute.

[18]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[19]  E. Schaeffer,et al.  Urinary markers in the detection of bladder cancer: what's new? , 2006, Current opinion in urology.

[20]  S. Sen,et al.  Aurora-A/STK15/BTAK enhances chromosomal instability in bladder cancer cells. , 2004, International journal of oncology.

[21]  H. Moch,et al.  Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. , 1997, Cancer research.

[22]  D. Chopin,et al.  Superficial bladder tumors. , 2002, European urology.

[23]  C. Heid,et al.  A novel method for real time quantitative RT-PCR. , 1996, Genome research.

[24]  Brian Schryver,et al.  A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers , 1998, The EMBO journal.

[25]  B. Monsarrat,et al.  Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2–M transition , 2004, Journal of Cell Science.

[26]  V. Paradis,et al.  p63 gene expression study and early bladder carcinogenesis. , 2007, Urology.

[27]  R. Tiguert,et al.  Prognostic markers in muscle invasive bladder cancer , 2002, World Journal of Urology.